Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole

Clinical Pharmacology and Therapeutics

Volumn 62, Issue 3, 1997, Pages 348-354

  Kivistö, Kari T ^a   Lamberg, Tommi S ^a   Kantola, Teemu ^a   Neuvonen, Pertti J ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BUSPIRONE; CYTOCHROME P450 ISOENZYME; ERYTHROMYCIN; ITRACONAZOLE;

ADULT; ARTICLE; BIOAVAILABILITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL FLICKER FUSION; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG BLOOD LEVEL; ENZYME INHIBITION; FEMALE; FIRST PASS EFFECT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTIFUNGAL AGENTS; AREA UNDER CURVE; BUSPIRONE; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; ERYTHROMYCIN; FEMALE; HUMANS; ITRACONAZOLE; MIXED FUNCTION OXYGENASES; PROTEIN SYNTHESIS INHIBITORS; PSYCHOMOTOR PERFORMANCE; SEROTONIN AGONISTS;

EID: 0030882158     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(97)90038-2     Document Type: Article

References (23)

1. Dollery C, editor. Therapeutic drugs; vol 2. Edinburgh: Churchill Livingstone, 1991:6136-40.
2. Bond AJ, Lader MH. Comparative effects of diazepam and buspirone on subjective feelings, psychological tests and the EEG. Int Pharmacopsychiatry 1981; 16:212-20.
3. Bond A, Lader M, Shrotriya R. Comparative effects of a repeated dose regime of diazepam and buspirone on subjective ratings, psychological tests and the EEG. Eur J Clin Pharmacol 1983;24:463-7.
4. Greenblatt DJ, Harmatz JS, Gouthro TA, Locke J, Shader RI. Distinguishing a benzodiazepine agonist (triazolam) from a nonagonist anxiolytic (buspirone) by electroencephalography: kinetic-dynamic studies. Clin Pharmacol Ther 1994;56:100-11.
5. 14C-buspirone HCl after intravenous and oral dosing in man [abstract]. Clin Pharmacol Ther 1985;37:210.
6. Gammans RE, Mayol RF, LaBudde JA. Metabolism and disposition of buspirone. Am J Med 1986; 80(suppl 3B):41-51.
7. Jajoo HK, Mayol RF, LaBudde JA, Blair IA. Metabolism of the antianxiety drug buspirone in human subjects. Drug Metab Dispos 1989;17:634-40.
8. Jajoo HK, Blair IA, Klunk LJ, Mayol RF. In vitro metabolism of the antianxiety drug buspirone as a predictor of its metabolism in vivo. Xenobiotica 1990; 20:779-86.
9. Gammans RE, Pfeffer M, Westrick ML, Faulkner HC, Rehm KD, Goodson PJ. Lack of interaction between cimetidine and buspirone. Pharmacotherapy 1987;7:72-9.
10. Buch AB, Van Harken DR, Seidehamel RJ, Barbhaiya RH. A study of pharmacokinetic interaction between buspirone and alprazolam at steady state. J Clin Pharmacol 1993;33:1104-9.
11. Olkkola KT, Aranko K, Luurila H, Hiller A, Saarnivaara L, Himberg JJ, et al. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 1993;53:298-305.
12. Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;55:481-5.
13. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;56:601-7.
14. Gaillard Y, Gay-Montchamp JP, Ollagnier M. Simultaneous screening and quantitation of alpidem, zolpidem, buspirone, and benzodiazepines by dual-channel gas chromatography using electron-capture and nitrogen-phosphorous detection after solid-phase extraction. J Chromatogr 1993;622:197-208.
15. Betto P, Meneguz A, Ricciarello G, Pichini S. Simultaneous high-performance liquid chromatographic analysis of buspirone and its metabolite l-(2-pyrimidinyl)-piperazine in plasma using electrochemical detection. J Chromatogr 1992;575:117-21.
16. Laakso S, Scheinin M, Anttila M. Determination of erythromycin base and 2′-acetylerythromycin in human plasma using high-performance liquid chromatography with electrochemical detection. J Chromatogr 1990;526:475-86.
17. Allenmark S, Edebo A, Lindgren K. Determination of itraconazole in serum with high-performance liquid chromatography and fluorescence detection. J Chromatogr 1990;532:203-6.
18. Backman JT, Olkkola KT, Neuvonen PJ. Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 1996;59:7-13.
19. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB. Identification of rifampicin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992;90:1871-8.
20. Kivistö KT, Bookjans G, Fromm MF, Griese EU, Münzel P, Kroemer HK. Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue. Br J Clin Pharmacol 1996;42:387-9.
21. Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, et al. First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 1996;60:14-24.
22. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 1996;59:491-502.
23. Goa KL, Ward A. Buspirone: a preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs 1986;32:114-29.